Szczech Lynda Anne
Duke University Medical Center, Department of Medicine, Division of Nephrology, Box 3646, Durham, NC 27710, USA.
Curr Opin HIV AIDS. 2009 May;4(3):167-70. doi: 10.1097/COH.0b013e328329c646.
This review will summarize the relevant literature supporting the early initiation of antiretroviral therapy among persons with HIV and kidney disease.
Recent guidelines support the initiation of antiretroviral therapy among persons with HIVAN as soon as the diagnosis of kidney disease is made. However, few patients with HIV and kidney disease undergo renal biopsy to determine the histology of their renal lesion. Observational studies, however, suggest that antiretroviral therapy is associated with a lesser risk of new AIDS defining illness and mortality associated with the presence of proteinuria or increased creatinine. These abnormalities are seen in a larger proportion of persons with HIV than only those that undergo biopsy. Therefore, these markers could describe the subgroup of patients at highest risk of poor outcomes and potentially prompt the consideration of earlier initiation of therapy on an individual basis.
Early initiation of antiretroviral therapy probably improves outcomes among persons with HIVAN. The presence of proteinuria or an elevated creatinine could prompt consideration for early initiation of antiretroviral therapy on a case-by-case basis.
本综述将总结支持HIV感染者及肾病患者尽早开始抗逆转录病毒治疗的相关文献。
近期指南支持一旦确诊肾病,HIV相关性肾病患者应尽快开始抗逆转录病毒治疗。然而,很少有HIV合并肾病的患者接受肾活检以确定其肾脏病变的组织学特征。不过,观察性研究表明,抗逆转录病毒治疗与新发艾滋病定义疾病的风险降低以及与蛋白尿或肌酐升高相关的死亡率降低有关。这些异常在HIV感染者中出现的比例高于仅接受活检的患者。因此,这些标志物可以描述预后不良风险最高的患者亚组,并可能促使在个体基础上考虑更早开始治疗。
尽早开始抗逆转录病毒治疗可能会改善HIV相关性肾病患者的预后。蛋白尿或肌酐升高的情况可促使逐案考虑尽早开始抗逆转录病毒治疗。